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Prevalence of Amyloid PET Positivity in Dementia Syndromes
A Meta-analysis
Rik Ossenkoppele, PhD; Willemijn J. Jansen, MSc; Gil D. Rabinovici, MD; Dirk L. Knol, PhD; Wiesje M. van der Flier, PhD; Bart N. M. van Berckel, MD, PhD;
Philip Scheltens, MD, PhD; Pieter Jelle Visser, MD, PhD; and the Amyloid PET Study Group
IMPORTANCE Amyloid-β positron emission tomography (PET) imaging allows in vivo detection
of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its diagnostic
utility is still unclear because amyloid plaques also occur in patients with non–AD dementia.
OBJECTIVE To use individual participant data meta-analysis to estimate the prevalence of
amyloid positivity on PET in a wide variety of dementia syndromes.
DATA SOURCES The MEDLINE and Web of Science databases were searched from January
2004 to April 2015 for amyloid PET studies.
STUDY SELECTION Case reports and studies on neurological or psychiatric diseases other than
dementia were excluded. Corresponding authors of eligible cohorts were invited to provide
individual participant data.
DATA EXTRACTION AND SYNTHESIS Data were provided for 1359 participants with clinically
diagnosed AD and 538 participants with non–AD dementia. The reference groups were 1849
healthy control participants (with amyloid PET) and an independent sample of 1369 AD
participants (with autopsy data).
MAIN OUTCOMES AND MEASURES Estimated prevalence of positive amyloid PET scans
according to diagnosis, age, and apolipoprotein E (APOE) ε4 status, using the generalized
estimating equations method.
RESULTS The likelihood of amyloid positivity was associated with age and APOE ε4 status. In AD
dementia, the prevalence of amyloid positivity decreased from age 50 to 90 years in APOE ε4
noncarriers (86% [95% CI, 73%-94%] at 50 years to 68% [95% CI, 57%-77%] at 90 years; n = 377)
and to a lesser degree in APOE ε4 carriers (97% [95% CI, 92%-99%] at 50 years to 90% [95% CI,
83%-94%] at 90 years; n = 593; P < .01). Similar associations of age and APOE ε4 with amyloid
positivity were observed in participants with AD dementia at autopsy. In most non–AD dementias,
amyloid positivity increased with both age (from 60 to 80 years) and APOE ε4 carriership.
Total Participants
Amyloid Positivity, % (95% CI)
Age 60 y Age 80 y
Dementia with Lewy bodies
APOE ε4 carrier 16 63 (48-80) 83 (67-92)
APOE ε4 noncarrier 18 29 (15-50) 54 (30-77)
Frontotemporal dementia
APOE ε4 carrier 48 19 (12-28) 43 (35-50)
APOE ε4 noncarrier 160 5 (3-8) 14 (11-18)
Vascular dementia
APOE ε4 carrier 30 25 (9-52) 64 (49-77)
APOE ε4 noncarrier 77 7 (3-18) 29 (17-43)
CONCLUSIONS AND RELEVANCE Among participants with dementia, the prevalence of amyloid
positivity was associated with clinical diagnosis, age, and APOE genotype. These findings
indicate the potential clinical utility of amyloid imaging for differential diagnosis in early-onset
dementia and to support the clinical diagnosis of participants with AD dementia and
noncarrier APOE ε4 status who are older than 70 years.
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M ore than 35 million people worldwide experience de-mentia, with Alzheimer disease (AD) hallmark pa-thologies amyloid-β plaques and neurofibrillary
tangles as the most common cause.1 Accurately determining
the cause of dementia during life is essential to developing and
implementing disease-specific therapies. However, a diagno-
sis based on clinical criteria alone has limited capacity to de-
termine the histopathological cause of dementia. For ex-
ample, the clinical diagnosis of probable AD shows only modest
sensitivity (71%-81%) and specificity (approximately 70%)
against postmortem examination,2,3 which potentially con-
founds clinical trials in AD.4,5 Development of amyloid-β–
specific positron emission tomography (PET) tracers6-9 now en-
able human in vivo detection of fibrillar amyloid-β in neuritic
plaques. Incorporating amyloid imaging into the diagnostic
workup can lead to change in diagnosis,10-12 increased diag-
nostic confidence,11 and altered patient management.10,12 Ap-
proval by the US Food and Drug Administration (FDA) for
[18F]florbetapir (in 2012), [18F]flutemetamol (in 2013), and
[18F]florbetaben (in 2014) supports potential application of
amyloid imaging in clinical practice.13
However, the clinical utility of amyloid imaging is poten-
tially limited by a proportion of patients with non–AD demen-
tia and cerebral amyloid-β plaques.14,15 To correctly interpret the
clinical significance of amyloid PET results, clinicians need to
understand the prevalence of amyloid positivity across differ-
ent types of dementia and how this is associated with demo-
graphic, genetic, and cognitive factors. Most amyloid PET stud-
ies to date come from single centers with modest sample sizes.16
Therefore, we conducted an individual participant meta-
analysis to estimate the prevalence of amyloid positivity in a
large sample encompassing a variety of dementia syndromes
and to evaluate relationships between amyloid PET positivity
and age, sex, education, global cognition, and the AD risk-
allele apolipoprotein E (APOE) ε4. We also compared the preva-
lence of amyloid positivity between participants with demen-
tia and participants who were cognitively healthy, and tested
associations of amyloid prevalence with age and APOE geno-
type in an independent autopsy sample of participants with AD.
Methods
Study Selection
Informed consent was obtained from all participants or their
assigned surrogate decision makers, and the institutional re-
view boards for human research of the participating centers
approved all studies. The MEDLINE and Web of Science data-
bases were searched from January 2004 (when the first hu-
man amyloid PET study was published with carbon 11–labeled
Pittsburgh Compound B [{11C}PIB]6) to April 7, 2015, on amy-
loid PET studies in patients with dementia. The search terms
used were PET and amyloid or abeta or PET tracer (ie, PIB,
Pittsburgh, florbetapir, AV-45, florbetaben, or flutemetamol).
Due to its affinity to both amyloid and tau pathology,
2-(1-{6-[(2-fluorine 18–labeled fluoroethyl)methylamino]-2-
napthyl}ethylidene) malononitrile ([18F]FDDNP) was not
included.17 The search resulted in 3250 studies. Titles and ab-
stracts were reviewed and 227 relevant full-text articles were
retrieved to assess their eligibility. Studies were excluded if they
presented case reports, included duplicate participants, or in-
volved neurological or psychiatric diseases other than demen-
tia. The search identified 40 unique cohorts. We asked 37 study
contact persons to provide participant-level data on amyloid
status, age, sex, education, APOE ε4 status,18 Mini-Mental State
Examination (MMSE) score, and Clinical Dementia Rating (CDR)
scale score (3 cohorts published their studies after our inclu-
sion stop in April 2014). Eight contact persons declined or did
not respond, leaving participant-level data from 29 cohorts for
analysis (Figure 1). Seven cohorts provided additional unpub-
lished participant-level data, acquired using peer-reviewed
clinical and PET procedures (eTable 1A in the Supplement).
Only 1 cohort provided data that were not yet published in a
peer-reviewed journal (n = 37, participants with dementia
only). Following the same procedure, we selected 1849 healthy
control participants from 23 cohorts (eFigure 1 in the Supple-
ment), defined as participants who performed cognitive test-
ing within normal limits and without any major neurological
or psychiatric disorder.19 The quality of primary reports from
each cohort was systematically assessed by examining the set-
ting, generalizability, selection, measurements, reference, bias,
participant flow, descriptives, outcome, and dichotomiza-
tion using combined STROBE20 and QUADAS21 guidelines
(eTable 2A and eTable 2B in the Supplement). All cohorts re-
ported their studies following the STROBE and QUADAS guide-
lines, although bias could not be assessed in 17 of 29 demen-
tia cohorts and 13 of 23 control cohorts.
Data Collection and Operationalization
Information on study procedures, extracted from the publi-
cations or provided by the study contact person, was used to
create a common set of variables.
Participants
Participants met diagnostic criteria for AD (including the atypi-
cal variants posterior cortical atrophy and logopenic-variant
primary progressive aphasia), frontotemporal dementia (in-
cluding behavioral, semantic, and progressive nonfluent vari-
ants), dementia with Lewy bodies (DLB), vascular dementia,
and corticobasal syndrome. All diagnoses were made clini-
cally without using amyloid PET or cerebrospinal fluid bio-
marker information. Detailed characteristics for each study are
in eTable 1 in the Supplement. For an indirect comparison be-
tween in vivo and postmortem prevalence of amyloid positiv-
ity, the National Alzheimer’s Coordinating Center (NACC)
database22 provided autopsy data of participants who were
clinically diagnosed with probable AD dementia at their last
visit. Participants who met the Consortium to Establish a Reg-
istry for Alzheimer’s Disease criteria23 for definite, probable,
or possible AD (indicating presence of moderate to frequent
neuritic plaques) were considered amyloid positive.
PET Procedures
The PET scans were dichotomized (amyloid positive or nega-
tive) using quantitative thresholds or visual reads according
to the method used at the study site. Detailed PET proce-
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dures for all participating cohorts are presented in eTable 1 in
the Supplement.
APOE Genotype and Clinical Measures
Information on APOE genotype was available for 1370 partici-
pants (72.2%). The MMSE24 (measure of global cognition) was
available for 1817 participants with dementia (95.8%) and the
CDR scale25 (indicator of disease severity based on caregiver
information) was available for 1329 participants with demen-
tia (70.0%). Participants with missing data for any of those vari-
ables did not differ in amyloid positivity compared with par-
ticipants with complete data sets.
Statistical Analysis
We conducted a meta-analysis with individual participant data.
Baseline characteristics were compared using analysis of vari-
ance and Fisher exact tests where appropriate. Generalized es-
timating equations (GEE, using SPSS software [IBM], version
21.0) were used to estimate probabilities for amyloid positiv-
ity on PET and odds ratios. Generalized estimating equations
was the method of choice for the study as it allows analysis of
binary-correlated data, such that participant-level data from
all cohorts can be modeled while simultaneously accounting
for participants within studies. A logit link function for bi-
nary outcome with an exchangeable correlation structure was
assumed to account for within-study correlation. Analyses were
conducted using the total study population, unless specified
otherwise.
The main analyses were performed with diagnosis, age, sex,
and APOE genotype as independent variables. Age was en-
tered as a continuous measure centered at the median. We
tested 2-way and 3-way interactions between variables, and
these terms were retained in the model if they appeared sig-
nificant by the Wald statistical test (indicated in Table foot-
notes and Figure legends). The GEE method derived unstan-
dardized βs, and standard errors (SE) of the main effect were
reported. Estimated probabilities and 95% CIs from the GEE
analysis were used in Tables and Figures. These GEE probabili-
ties were compared with the observed probabilities to deter-
mine the goodness-of-fit between actual data and the smoothed
GEE estimates. The relationship between amyloid positivity on
PET and MMSE scores was examined using general linear mixed
models including education as an additional covariate.
The degree of heterogeneity across cohorts was assessed
in several ways. In the total sample, the random intercept vari-
ance related to a study was estimated in a random effect analy-
sis with age, APOE ε4 carriership, and interactions by the “xt-
melogit” function from STATA (StataCorp), version 12.0. This
variance was expressed as an intraclass correlation coeffi-
cient. For each diagnostic group, we assessed heterogeneity
within 10-year strata using the I2 statistic26 generated by a ran-
dom-effects meta-analysis in STATA. An I2 statistic value
greater than 50% indicates substantial heterogeneity.26 Across
the age range, study variability was visualized by plotting
prevalence estimates for each AD and frontotemporal demen-
tia cohort that contained at least 5 participants.
Significance level was set at a 2-sided P value less than .05.
All reported P values were not corrected for multiple compari-
sons. Secondary analyses using Bonferroni correction were also
conducted, and results for which interpretation changed are
noted. R (R Foundation for Statistical Computing), version 3.1.2,
and GraphPad Prism (GraphPad Software), version 6.0 were
used for the Figures.
Results
The study included 1897 participants with a clinical diagnosis
of dementia (AD, 1359 participants; frontotemporal demen-
tia, 288 participants; DLB, 51 participants; vascular dementia,
138 participants; corticobasal syndrome, 61 participants) and
1849 healthy control participants with PET data (Table 1).
From the NACC database, 1369 participants with AD demen-
tia and autopsy data were included (eTable 2 in the Supple-
ment). Amyloid positivity refers to positive (abnormal) amy-
loid PET scans or presence of moderate-to-frequent plaques
on neuropathological examination.
Figure 1. Flow Diagram of Participant Selection for Dementia Syndromes
3250 Records identified through
database searching






51 Dementia with Lewy bodies
61 Corticobasal syndrome
3 Cohorts excluded (articles published after
the inclusion stop [5 articles])
8 Cohorts excluded (study contact person
refused or did not respond [30 articles])
3023 Records excluded based on review of title
and abstract
1376 Other topic, method, or design




396 Inclusion of controls
and/or MCI patients only
7 Articles excluded after full review
4 Inclusion of prodromal Alzheimer
disease only
3 Pilot or preliminary articles
40 Unique cohorts identified (220 articles)
37 Cohorts for which individual patient
data sought (215 articles)
227 Full-text articles assessed
for eligibility
MCI indicates mild cognitive impairment. MEDLINE and Web of Science
databases were searched from January 2004 to April 2015.
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Prevalence of Amyloid Positivity According to Diagnosis,
Age, and APOE
In AD dementia, the mean prevalence of amyloid positivity was
88% (95% CI, 85% to 90%, Figure 2A). The prevalence de-
creased with age from 93% (95% CI, 90% to 95%) at age 50 to
79% (95% CI, 73% to 85%) at age 90 (β for change in GEE esti-
mated prevalence of amyloid positivity per year, −0.032 [95%
CI, −.050 to −.014], P < .001). This association differed accord-
ing to APOE ε4 status (Figure 2C and Figure 2D). In APOE ε4
carriers, the prevalence remained at least 90% regardless of
age, whereas the prevalence in noncarriers declined from 86%
(95% CI, 73% to 94%) at age 50 years to 68% (95% CI, 57% to
77%) at age 90 years (β, −0.034 [95% CI, −.058 to −.010], P < .01).
Similar associations were found for age and APOE ε4 with amy-
loid positivity as assessed using neuropathological criteria in
an independent cohort of AD dementia participants with au-
topsy data (Figure 2B). The mean prevalence estimate for the
autopsy data was 85% (95% CI, 82% to 87%), with stable esti-
mates across age in APOE ε4 carriers and a decreasing preva-
lence with increasing age in noncarriers.
Mean amyloid positivity in non–AD dementias was high-
est in DLB (51% [95% CI, 33% to 69%]), followed by vascular
dementia (30% [95% CI, 21% to 42%]) and frontotemporal de-
mentia (12% [95% CI, 8% to 18%]). In these dementias, amy-
loid positivity increased with age (β, 0.042 [95% CI, .012 to .071],
P < .01), Figure 2A and Table 2). The rate of increase was in-
dependent of APOE genotype but APOE ε4 carriers had higher
overall mean prevalence estimates than noncarriers (18% [95%
CI, 8% to 28%]) (Figure 2C and Figure 2D). In participants with
corticobasal syndrome, the overall prevalence of amyloid posi-
tivity was 38% (95% CI, 23% to 54%), which decreased with age
(β, −0.073 [95% CI, −.130 to −.016], P < .05), independent of
APOE ε4 status. This analysis was no longer statistically sig-
nificant after Bonferroni correction (P = .15). Repeating all
analyses above using only participant data from published co-
horts (28 of 29 cohorts) yielded essentially the same results
(eTable 3 in the Supplement).
The prevalence of amyloid positivity was not signifi-
cantly associated with sex in both AD (women, 89% [95% CI,
86% to 91%]; men, 86% [95% CI, 83% to 89%], β for change in
GEE estimated prevalence of amyloid positivity for men vs
women, −0.287 [95% CI, −.620 to .046], P = .09) and non–AD
dementias (women, 26% [95% CI, 19% to 34%); men, 21%
[95% CI, 15% to 29%], β, −0.134 [95% CI, −.447 to .299],
P = .54). Years of education was also not associated with the
prevalence of amyloid positivity in AD (β for change in GEE
estimated prevalence of amyloid positivity per year of educa-
tion, 0.016 [95% CI, −0.31 to .063], P = .51) and non–AD
dementias (β, 0.025 [95% CI, −.038 to .088], P = .44).
For comparison with the GEE estimated probabilities for
amyloid positivity on PET, the observed probabilities are pro-
vided in Table 3. Estimates of overall amyloid positivity in dif-
ferent subtypes of AD and frontotemporal dementia are pro-
vided in eTable 4 in the Supplement.
Amyloid Positivity Prevalence Relative to Controls
The mean prevalence of amyloid positivity was higher in the
total group of participants with AD (β for difference in GEE es-


















Age, mean (SD), y 69.4 (9.3) 65.9 (8.2)b 74.5 (8.5)b 69.1 (7.6) 66.6 (7.5) 68.1 (14.0)
Age, median (range), y 69 (38-95) 66 (41-85) 75 (46-90) 68 (55-87) 68 (40-88) 68 (40-88)
Age groups, No. (%), y
<55 58 (4.3) 25 (8.7) 2 (1.4) 2 (3.3) 209 (11.3)
55-59 164 (12.1) 37 (12.8) 4 (2.9) 4 (7.8) 6 (9.8) 128 (6.9)
60-64 201 (14.8) 62 (21.5) 12 (8.7) 12 (23.5) 16 (26.2) 173 (9.4)
65-69 249 (18.3) 63 (21.9) 20 (14.5) 12 (23.5) 11 (18.0) 352 (19.0)
70-74 259 (19.1) 62 (21.5) 25 (18.1) 11 (21.6) 20 (32.8) 334 (18.1)
75-79 212 (15.6) 29 (10.1) 32 (23.2) 7 (13.7) 5 (8.2) 305 (16.5)
80-84 147 (10.8) 9 (3.1) 27 (19.6) 3 (5.9) 193 (10.4)
≥85 69 (5.1) 1 (0.3) 16 (11.6) 2 (3.9) 1 (1.6) 155 (8.4)
Men, No. (%) 721 (53.1) 148 (51.4) 85 (61.6) 19 (37.3) 29 (47.5) 756 (41.4)
Education, mean (SD), y 13.8 (3.6) 13.6 (3.5) 10.1 (4.2)b 13.7 (3.1) 13.7 (3.6) 15.1 (3.3)
MMSE score, mean (SD)c 21.8 (4.7)b 23.8 (5.5) 19.4 (5.8)b 22.9 (5.4) 22.5 (6.3) 29.1 (1.2)
Global CDR, mean (SD) d 0.9 (0.4) 0.8 (0.6) 1.2 (0.7)b 1.1 (0.7)b 0.9 (0.6) 0
APOE ε4 carrier/noncarrier
(% carrier)e
593/377 (61.1)b 48/160 (23.1) 30/77 (28.0) 16/18 (47.1)b 17/34 (33.3) 478/1091 (30.5)
Abbreviations: APOE, apolipoprotein E; CDR, Clinical Dementia Rating; MMSE,
Mini-Mental State Examination.
a Participant characteristics were compared between diagnostic groups using
analysis of variance and Fisher exact tests, with post hoc Bonferroni tests for
all possible pairs.
b Pairwise comparisons were statistically significant for the group indicated.
c Range: 0 to 30, lower scores indicate worse global cognition.
d Range: 0 to 3, higher scores indicate more advanced disease severity.
e APOE data missing in 27.8% of dementia participants and 15.9% of control
participants.
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timate compared with the control group, 3.215 [95% CI, 3.013
to 3.417], P < .001), DLB (β, 1.231 [95% CI, .663 to 1.799],
P < .001), and corticobasal syndrome (β, 0.787 [95% CI, .250 to
1.324], P < .001), similar in those with vascular dementia
(β, 0.090 [95% CI, −.294 to .475], P = .65), and lower in those
with frontotemporal dementia (β, −0.691 [95% CI, −1.065 to
−.318], P < .001) compared with cognitively normal partici-
pants (Figure 2A and Figure 2D).
Amyloid Positivity as Discriminator
Between Clinical Dementia Syndromes
Figure 3 displays the odds ratios for discrimination of AD from
non–AD participants using amyloid PET. Odds ratios de-
creased in all non–AD dementias with increasing age, except
for corticobasal syndrome participants.
Association of Amyloid Positivity With Global Cognition
Amyloid positivity was associated with lower MMSE scores in
both AD dementia (amyloid positive, 21.2 [95% CI, 20.2 to 22.2];
amyloid negative, 22.2 [95% CI, 20.9 to 23.4]; P < .05) and
non–AD dementia (amyloid positive, 20.6 [95% CI, 19.2 to 21.9];
amyloid negative, 23.2 [95% CI, 22.2 to 24.3]; P < .001). Among
non–AD dementias, the association between MMSE scores and
amyloid status was significant for DLB (amyloid positive,
19.6 [95% CI, 17.3 to 21.9]; amyloid negative, 25.3 [95% CI, 22.9
to 27.8]; P < .001), and vascular dementia (amyloid positive,
19.5 [95% CI, 15.9 to 23.1]; amyloid negative, 22.3 [95% CI, 18.9
to 25.7]; P < .05; no longer significant after Bonferroni correc-
tion [P = .07]), but not for frontotemporal dementia (amyloid
positive, 22.4 [95% CI, 20.3 to 24.4]; amyloid negative,
23.9 [95% CI, 23.0 to 24.8]; P = .17) and CBS (amyloid positive,













































































Autopsy APOE ε4+ (n = 491)
PET APOE ε4+ (n = 593)
Autopsy APOE ε4– (n = 501)
PET APOE ε4– (n = 377)Dementia with Lewy bodies (n = 51)
Alzheimer disease (n = 1359)
Frontotemporal dementia (n = 288)
Vascular dementia (n = 138)
Corticobasal syndrome (n = 61)
Control (n = 1849)
Dementia with Lewy bodies (n = 16)
Alzheimer disease (n = 593)
Frontotemporal dementia (n = 48)
Vascular dementia (n = 30)
Corticobasal syndrome (n = 17)
Control (n = 478)
Dementia with Lewy bodies (n = 18)
Alzheimer disease (n = 377)
Frontotemporal dementia (n = 160)
Vascular dementia (n = 77)
Corticobasal syndrome (n = 34)
Control (n = 1091)
PET indicates positron emission tomography. The curves were plotted using the
point estimates generated by generalized estimating equations and are within
the age limits of the diagnostic groups. The models were adjusted for study
effects. The 95% CIs are presented in Table 2 and eFigure 3 in the Supplement.
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21.6 [95% CI, 18.5 to 24.7]; amyloid negative, 23.0 [95% CI, 20.8
to 25.2]; P = .48).
PET Tracers and Procedures
In most participants, [11C]PIB was used (n = 1330), followed by
[18F]florbetapir (n = 328), [18F]flutemetamol (n = 120), and
[18F]florbetaben (n = 119). On post hoc analyses, there were no
significant differences in prevalence of amyloid positivity be-
tween [11C]PIB and [18F]florbetapir (eTable 6 in the Supplement,
[18F]flutemetamol and [18F]florbetaben were excluded from
this analysis due to their sample size). The method of assess-
ment (visual reads [n = 1123] or quantitative thresholds
[n = 774]) and type of data acquisition (static [n = 1318] or dy-
namic [n = 579]) were not associated with the prevalence of
amyloid positivity either.
Assessment of Study-Related Heterogeneity
In the total study population, the intraclass correlation coef-
ficient for study-related random intercept variance was 0.046,
indicating minor heterogeneity across cohorts. Within age and
diagnostic groups, heterogeneity was not substantial accord-
ing to the I2 statistic, except for the vascular dementia group
with participants older than 80 years (eTable 7 in the Supple-
ment). Upon visual inspection, variability in prevalence esti-
mates as a function of age in cohorts with at least 5 partici-
pants was limited (eFigure 3 in the Supplement).
Discussion
The main findings of this individual participant meta-
analysis were that the prevalence of amyloid on PET de-
creased with age in participants diagnosed with AD (greatest
in APOE ε4 noncarriers) and increased with age in most non–AD
dementias. The convergence of amyloid positivity across de-
mentias with increasing age suggests that amyloid imaging
might have the potential to be most helpful for differential di-
agnosis in early-onset dementia, particularly if the goal is to
rule-in AD dementia. However, the high concordance be-
tween PET and pathology suggests that amyloid imaging might
have the potential to be used to rule-out AD dementia regard-
less of age. Furthermore, amyloid in non–AD dementia may
be clinically important as amyloid positivity was associated
with worse global cognition. Data from this study may in-
form research into the clinical application of amyloid PET and
highlight the necessity of biomarker-based participant selec-
tion for clinical trials.
A negative amyloid PET scan was observed in 12% of
clinically diagnosed AD dementia participants and was most
common in older APOE ε4 noncarriers. The latter finding is
consistent with 2 recent phase 3 trials with humanized anti–
amyloid-β monoclonal antibodies.4,5 The “AD phenocopy” was
most prevalent in older and APOE ε4 negative participants and
may best be explained by a mix of age-related pathologies (eg,
hippocampal sclerosis, argyrophilic grain disease, or tangle-
predominant dementia27-29) that preferentially target the lim-
bic system, resulting in a memory-predominant presentation


















Dementia with Lewy bodies (n = 51)
Frontotemporal dementia (n = 288)
Vascular dementia (n = 138)
Corticobasal syndrome (n = 61)
AD indicates Alzheimer disease. The curves were plotted using the point
estimates generated by generalized estimating equations and represent odds
ratios of amyloid positivity for the different non–AD dementia syndromes (with
patients with AD dementia as the reference group) as a function of age. The
models include amyloid status on PET (positive or negative), age (as a
continuous variable), and an interaction between amyloid status and age. The
curves are within the age limits of the diagnostic groups.
Table 3. Observed Probabilities of Amyloid Positivity on PET Across Diagnostic and Age Groupsa












All 1193/1359 (87.8) 35/288 (12.2) 42/138 (30.4) 26/51 (51.0) 23/61 (37.7) 448/1849 (24.2)
50 51/58 (87.9) 0/25 (0) 1/2 (50.0) 1/2 (50.0) 2/209 (1.0)
60 333/365 (91.2) 10/99 (10.1) 1/16 (6.3) 6/16 (37.5) 11/22 (50.0) 35/301 (11.6)
70 453/508 (89.2) 22/125 (17.6) 9/45 (20.0) 14/23 (60.9) 8/31 (25.8) 163/686 (23.8)
80 303/359 (84.4) 3/38 (7.9) 25/59 (42.4) 6/10 (60.0) 3/5 (60.0) 172/498 (34.5)
90 53/69 (76.8) 0/1 (0) 6/16 (37.5) 0/2 (0) 0/1 (0) 76/155 (49.0)
Abbreviations: PET, positron emission tomography.
a Observed probabilities (percentages) of amyloid positivity on PET were
calculated by No. amyloid positive/No. total group.
b Age groups: 50 includes participants 54 years and younger; 60, 55-64 years;
70, 65-74 years; 80, 75-84 years; 90, 85 years and older. All includes the
entire age range.
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that may be mistaken for AD, as well as false-negative PET
scans. False-negative PET scans may reflect insensitivity to de-
tect advanced amyloid pathology, possibly caused by dis-
tinct conformations of amyloid plaques, amyloid deposition
in reference regions, or severe neurodegeneration. This is likely
only a partial explanation because, with a few exceptions,30,31
PET and neuropathological assessments correspond well,32 and
the independent samples of AD dementia participants with au-
topsy or PET showed similar prevalence estimates. Alterna-
tively, elderly people may develop AD dementia in the pres-
ence of a lower amyloid burden (potentially not captured by
PET) due to age-related diminished resilience (cognitive re-
serve theory33) or the cumulative effect of comorbid patholo-
gies (double-hit hypothesis34). Future studies with antemor-
tem amyloid PET and postmortem neuropathological
examination are needed to identify which proportion of amy-
loid negative PET scans can be attributed to clinical misclas-
sification or to false-negative PET findings in patients with clini-
cal AD dementia.
In participants with frontotemporal dementia, vascular de-
mentia, and DLB, the prevalence of amyloid positivity in-
creased with age. A proportion of these participants may have
been clinically misdiagnosed, with AD as the pathological sub-
strate for their dementia.2 Another explanation is that amyloid
is present as secondary pathology whereas the clinical syn-
drome is driven by non–AD pathologies.15,35,36 The finding that
the prevalence of amyloid positivity increases with presence of
the 2 major risk factors for sporadic AD, aging and APOE ε4 geno-
type, supports the latter interpretation. The advent of novel tau
PET tracers37-39 could provide further clues when 2 patholo-
gies manifest simultaneously, because prominent neocortical
tau pathology is typically absent in patients with DLB, vascu-
lar dementia, and some frontotemporal dementia subtypes.
In corticobasal syndrome the prevalence of amyloid posi-
tivity decreased with age. Corticobasal syndrome is a clini-
cally and pathologically heterogeneous entity including mo-
tor, behavioral, and cognitive features.40 Corticobasal
syndrome is mostly associated with underlying 4-repeat tauo-
pathy (corticobasal degeneration or progressive supra-
nuclear palsy), but up to 25% of patients have AD as the pri-
mary pathology at autopsy.41,42 This study suggests that AD
may be the causative pathology in young corticobasal syn-
drome patients, whereas a primary tauopathy becomes more
likely with increasing age.
This study underscores that clinical diagnosis, age, and
APOE status are crucial factors when ordering and interpret-
ing clinical amyloid PET scans. The likelihood of detecting in-
cidental amyloid pathology increased with advancing age in
both controls and non–AD dementia patients. In line with re-
cently proposed appropriate use criteria,43 this suggests that
amyloid imaging might be particularly helpful for differential
diagnosis in early-onset dementia. In contrast, the conver-
gence between AD and non–AD dementia participants with age
warrants careful interpretation of positive amyloid PET scans
in older patients. Also, amyloid imaging does not seem justi-
fied in APOE ε4 carriers to confirm their clinical diagnosis of
AD dementia, as the prevalence of amyloid positivity re-
mained around 90% regardless of age. In noncarriers, how-
ever, an amyloid PET scan may be informative in patients older
than 70 years as the prevalence declined to 78% and further
decreased to 68% at age 90. Although not recommended for
routine diagnostic assessment,44 knowledge of APOE status
may be helpful when considering amyloid assessment in clini-
cal practice.
There are a number of limitations that need to be consid-
ered in interpreting this study. First is its limited generalizabil-
ity as participants were highly educated (mean, 14.3 years of edu-
cation [SD, 3.6]) and relatively small proportions of AD (15.9%)
and non–AD (10.9%) dementia participants were older than 80
years (this age range represents the largest segment in the com-
munity). This meta-analysis reflects a collection of studies con-
ducted in research memory clinics or focused epidemiological
studies with limits on age and medical comorbidities. Further-
more, data on race/ethnicity would have been informative be-
cause previous studies have reported differences in the preva-
lence of APOE ε4 and its association with cognitive decline
between white patients and black patients.45-47
Second, we pooled data from a large number of cohorts,
which may have introduced bias due to differences in study de-
signs. However, there was limited evidence for heterogeneity
across cohorts (eFigure 3 and eTable 7 in the Supplement).
Third, due to the absence of histopathological data in partici-
pants with amyloid PET, it remains unknown whether the
clinical diagnoses were correct and what type of pathologies
underlie non–AD diagnoses, particularly in amyloid positive par-
ticipants. Fourth, differences in acquisition methods did not
allow for harmonized PET data analysis across cohorts, so that
we adopted the methodology as specified by the different
study sites. This lack of standardization was addressed by ad-
justing all analyses for study effects. Also, post hoc analyses
showed no significant differences for assessment methods or
acquisition modus (eTable 6 in the Supplement).
Fifth, 70% of participants underwent [11C]PIB imaging,
although, from 2012 to 2014, the FDA approved three
18F-labeled PET tracers for clinical use.13 Although the
number of 18F-labeled amyloid PET scans was relatively
small, comparable prevalence estimates between [11C]PIB and
[18F]florbetapir suggests that present findings are coherent
across tracers.48 Sixth, although by design this is, to our knowl-
edge, the largest amyloid PET study in patients with demen-
tia, sample sizes in some non–AD dementia groups were rela-
tively small and resulted in wide CIs. In particular, the
prevalence estimates at the lower and higher age extremes in
models that include both age and APOE genotype in non–AD
dementias should be interpreted with caution.
Conclusions
Among participants with dementia, the prevalence of amy-
loid positivity was associated with clinical diagnosis, age, and
APOE genotype. These findings indicate the potential clinical
utility of amyloid imaging for differential diagnosis in early-
onset dementia and to support the clinical diagnosis of pa-
tients with AD dementia and noncarrier APOE ε4 status who
are older than 70 years.
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